Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incretin Action in Physiology and Diabetes
NCT04347252Phase 1Completed
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glucagon in type 2 diabetes mellitus (T2DM) (3 arms). Primary endpoints: Change in insulin secretion up to 1 hour and Hepatic glucose production up to 1 hour. Started Sep 2019; status: completed.
02
Drugs
glucagon
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04347252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347252.